A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (355 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-03-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: subjectpharmacodynamicssubjectsheartpd
  Phrases that lowered it: healthyand safetyfluticasonedaysingle
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past trials: 1698 (raises risk) · Sponsor's track record
• Primary purpose: other (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 349 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past termination rate: 4.9% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 4 (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, psychiatry: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses NCT01894386 · started 2013 · scored riskier than 1% of active trials completed
• A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects NCT02837380 · started 2016 · scored riskier than 3% of active trials completed
• Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler NCT01213849 · started 2010 · scored riskier than 0% of active trials completed
• Relovair PD PK in Chinese Healthy Subjects NCT01711463 · started 2012 · scored riskier than 2% of active trials completed
• ROTAHALER Device Optimization Study NCT01890863 · started 2013 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.